OOIR: Observatory of International Research

Papers

(The median citation count of Drug Resistance Updates is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance	264
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment	171
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors	159
Anticancer drug resistance: An update and perspective	121
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming	121
The role of alternative splicing in cancer: From oncogenesis to drug resistance	116
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy	108
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification	107
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance	104
Therapeutic strategies to overcome taxane resistance in cancer	101
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies	99
Novel nanomedicines to overcome cancer multidrug resistance	94
Hypoxia as a driver of resistance to immunotherapy	93
Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs	88
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance	79
A review on antimicrobial botanicals, phytochemicals and natural resistance modifying agents from Apocynaceae family: Possible therapeutic approaches against multidrug resistance in pathogenic microor	78
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses	77
Nanomedicine to target multidrug resistant tumors	71
Antimicrobial peptides for combating drug-resistant bacterial infections	67
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function	60
Repurposing old drugs to fight multidrug resistant cancers	58
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma	48
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects	47
Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance	45
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer	44

COVID-19 update: The race to therapeutic development	43
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer	43
Impact of cancer metabolism on therapy resistance – Clinical implications	42
The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology	42
Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci	42
Overcoming cancer chemotherapy resistance by the induction of ferroptosis	41
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine	40
Long non-coding RNA mediated drug resistance in breast cancer	38
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs	38
Metallothionein isoforms as double agents – Their roles in carcinogenesis, cancer progression and chemoresistance	37
Cross-resistance and drug sequence in prostate cancer	37
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition	37
Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance	34
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade	33
ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance	33
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents	31
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies	31
Current therapy and drug resistance in metastatic castration-resistant prostate cancer	31
Molecular Modeling Strategies of Cancer Multidrug Resistance	31
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma	29
In vitro biomimetic models for glioblastoma-a promising tool for drug response studies	29
The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells	28
N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells	26
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance	24
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers	23
The role of endolysosomal trafficking in anticancer drug resistance	23
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications	23
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer	23
Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome	22
Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia	22
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy	22
Precision medicine: Ray of hope in overcoming cancer multidrug resistance	21
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms	21
Targeted nanomedicine modalities for prostate cancer treatment	20
Epigenetic enzyme mutations as mediators of anti-cancer drug resistance	20
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability	20
Resistance-proof antimicrobial drug discovery to combat global antimicrobial resistance threat	20
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment	20
Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance	19
Revolutionizing non-conventional wound healing using honey by simultaneously targeting multiple molecular mechanisms	19
Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?	19
Paclitaxel resistance related to nuclear envelope structural sturdiness	18
Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia	17
Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance	17
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity	16
Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens?	15
Modulating undruggable targets to overcome cancer therapy resistance	15
Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer	14
KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m6A-dependent manner	14
Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression	12

Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation	12
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer	11
Understanding ER homeostasis and the UPR to enhance treatment efficacy of acute myeloid leukemia	11
Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy	11
Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins	11
Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer	11
Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer	11
Evolution of RND efflux pumps in the development of a successful pathogen	10
Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae	10
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica	10
Silver-dendrimer nanocomposite as emerging therapeutics in anti-bacteria and beyond	9
The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity	9
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA	9
Acquired non-thermal plasma resistance mediates a shift towards aerobic glycolysis and ferroptotic cell death in melanoma	9
CPSF6-mediated XBP1 3’UTR shortening attenuates cisplatin-induced ER stress and elevates chemo-resistance in lung adenocarcinoma	9
Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells	8
CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis	8
CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance	8
Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells	8
Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells	8
Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis	8
Antibiotic failure: Beyond antimicrobial resistance	8
A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+CD24- enriched breast cancer stem-like cells	7
Hallmarks of anticancer and antimicrobial activities of corroles	7
Aeromonas spp. from hospital sewage act as a reservoir of genes resistant to last-line antibiotics	7
CCT251545 enhances drug delivery and potentiates chemotherapy in multidrug-resistant cancers by Rac1-mediated macropinocytosis	7
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs	6
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance	6
Opposite evolution of pathogenicity driven by in vivo wzc and wcaJ mutations in ST11-KL64 carbapenem-resistant Klebsiella pneumoniae	6